Progyny 3Q 2026: Revenue $341.25M, EPS $0.32 — 10-Q Summary
Progyny reported 3Q 2026 revenue of $341.25M, up 8.9% YoY, and net income of $26.25M, up 89.4% YoY. Growth was driven by increased client and covered-life counts, improving gross margin to 24.5%. Fertility benefits and Progyny Rx revenue rose 11% and 6%, respectively. The company served 607 clients and 7.155M members as of September 30, 2026.
How this was made
The 30-second read
Why it matters
The Q3 2026 earnings beat underscores the company's ability to grow revenue and improve margins, which may attract investors seeking exposure to the growing fertility‑benefits market.
Market read
Strong earnings could lift PGNY and positively influence related health‑benefit stocks.
What to watch
Future growth depends on continued client acquisition and reimbursement environment for fertility benefits.
Background
Progyny is a U.S. benefits platform focused on fertility services and prescription drug coverage.
Ticker impact
Progyny reported Q3 2026 revenue of $341.25M and EPS $0.32, up 8.9% YoY and 13.3% YoY EPS, marking its first public disclosure of these results.
likely upward pressure as the market prices in the earnings beat and margin expansion
Revenue and EPS both exceeded prior‑year figures; gross margin improved and operating expenses fell, indicating better profitability.
Market effects
Highlights strength in fertility‑benefits and Rx segments, potentially boosting peer biotech and health‑benefit providers.
U.S. health‑benefit sector may see modest buying interest.
Limited to U.S. markets; no immediate global ripple.
Counterpoint
If the market has already priced in the earnings beat, the stock could face short‑term profit‑taking.
Key entities
- companyProgyny, Inc.
Provider of fertility‑benefits and Rx services, ticker PGNY.
